The subject has received systemic dexamethasone continuously at a dose >  mg/day for  weeks prior to the date of the screening assessment
Receive dexamethasone equivalent dose </= mg per day, stable or decreased for >/= three days prior to Day ;
Dexamethasone equivalent dose > mg per day;
Requires treatment with high dose systemic corticosteroids defined as dexamethasone >  mg/day or bioequivalent within at least  days of initiating therapy
<  mg dexamethasone daily (or equivalent if on another corticosteroid) at time of start of therapy; patients on a steroid taper post-surgery and are anticipated to be on <  mg at time of chemoradiation initiation will be eligible to consent but to initiate treatment on trial, the participant must be on <  mg or equivalent of steroids otherwise participate will be deemed a screen fail and be replaced
Requires treatment with high dose systemic corticosteroids defined as dexamethasone >  mg/day or bioequivalent within  days of initiating therapy
Treatment with high dose systemic corticosteroids defined as dexamethasone >  mg/day or bioequivalent within  days of initiating therapy
Treatment with high dose systemic corticosteroids defined as dexamethasone > mg/day or bioequivalent within  days of initiating therapy
The patient must be either off systemic steroids or be on stable dose of dexamethasone (max . mg/kg/day; maximum mg/day) at time of enrollment
EXCLUSION CRITERIA FOR STRATUM C: Patients may not be on immunosuppressive therapy, including corticosteroids (with the exception of physiologic replacement, defined as =< . mg/m^/day dexamethasone equivalent) at time of enrollment; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the study
Corticosteroids use exceeding a cumulative dose of  mg of dexamethasone during screening
Research participant must not require more than  mg three times daily TID of dexamethasone on the day of PBMC collection.
Phase I patients must not be receiving greater than  mg dexamethasone/day (or an equivalent amount of an alternative corticosteroid) for at least  week prior to treatment start
Has a diagnosis of immunodeficiency including human immunodeficiency virus (HIV) (HIV / antibodies) and is not on continuous daily immunosuppressive therapy within  days prior to the first dose of trial treatment; (an exception to this is the use of steroids for brain edema and resulting symptom); subjects may receive a stable or reducing dose of steroids (up to  mg dexamethasone or equivalent for at least  days prior to signing consent) to prevent or manage cerebral edema; subjects requiring over mg of dexamethasone per day on or five days prior to signing consent are excluded)
Received anti-myeloma treatment within  weeks or  pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone  mg/day for a maximum of  days before treatment
Corticosteroids will be allowed at enrollment and during the first month of treatment with T-DM after SRS, up to a dose of no more than  mg of dexamethasone daily or equivalent; patients that need to continue corticosteroids after the initial month will be allowed to continue in the protocol treatment if no further increase in dose is necessary; patients that need increase in dose of corticosteroid after initial month will be taken off protocol treatment
Patients who are on dexamethasone receiving >  mg/day in the two weeks prior to admission for intra-cerebral delivery of PVSRIPO
Requires treatment with high dose systemic corticosteroids defined as dexamethasone >  mg/day or bioequivalent for at least  consecutive days within  weeks of registration
Dexamethasone dose should be =<  mg/day or steroid equivalent prior to starting treatment; if higher doses are needed, consult with study chair
Patients on greater than  mg per day of dexamethasone within the  weeks prior to admission for PVSRIPO infusion
Ongoing or recent (within  days prior to study entry) use of high dose oral corticosteroids (>=  mg of dexamethasone daily or equivalent); intranasal and/or inhaled corticosteroid use is permitted
High doses of systemic corticosteroids within  days prior to first dosing; high dose is considered as >  mg of dexamethasone a day (or equivalent) for >  consecutive days
Is taking > mg/day of dexamethasone or its equivalent at the start of immunotherapy or has required > mg/day of dexamethasone or its equivalent for  consecutive days within  week of starting treatment
AT THE TIME OF INFUSION: Subjects should have been off other investigational antineoplastic therapy for two weeks prior to entry in this study; temozolomide will be allowed up to  hours pre-infusion; dexamethasone up to a total dose of  mg per day will be allowed if medically indicated
Patients must be clinically stable and off or on low-dose (no more than . mg/kg/day, max  mg/day dexamethasone) corticosteroid for at least one week prior to study registration
Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents; dexamethasone, or other corticosteroid medications, if used in the peri-operative period must be tapered to no more than . mg/kg/day, max  mg/day dexamethasone for at least one week before study registration; topical corticosteroids are acceptable
Systemic corticosteroid therapy >  mg of dexamethasone or equivalent per day at study entry
Patients on greater than  mg per day of dexamethasone within the  weeks prior to admission for DC-IT infusion
Research participant must not require more than  mg three times daily (TID) of dexamethasone on the day of PBMC collection.
Steroid use is allowed as long as dose has not increased within  weeks of scheduled M administration; whenever possible, the patient should be on a steroid dose that is equivalent to a dexamethasone dose of =<  mg daily at the time of treatment
Required steroid increase within  weeks of scheduled M administration; when possible, the patient should be on a dexamethasone equivalent dose of =<  mg daily at the time of treatment
Patients are allowed up to two cycles of high dose steroids (maximum total dose of  mg dexamethasone or equivalent) if needed for symptomatic disease before study enrollment
Patients currently receiving high dose systemic steroids for treatment of MM in excess of mg total dose of dexamethasone or equivalent, patients who received an investigational agent within  half-lives of the agent
Systemic corticosteroid therapy must be at a dose of =<  mg of dexamethasone or equivalent per day during the week prior to day 
Patients must be clinically stable and off or on low-dose (no more than . mg/kg/day, max  mg/day dexamethasone) corticosteroid for at least one week prior to study registration
Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents; patients must be on no more than . mg/kg/day, max  mg/day dexamethasone for at least one week before study registration; topical corticosteroids are acceptable
Patients on total daily dose of dexamethasone greater than  mg
Patients needing more than  mg dexamethasone per day at the time of start of WBRT will not be eligible to participate in the study; however, patients will be allowed entry into the study if it is medically safe to reduce the daily dose of dexamethasone to  mg or less from the day of the start of WBRT; the dexamethasone dose for such patients may be increased beyond  mg per day during the course of treatment if medically necessary; this increased need for dose should be communicated to the studys principal investigator, Dr Mohindra at the University of Maryland
Patients must be clinically stable and off or on low-dose (no more than . mg/kg/day, max  mg/day dexamethasone) corticosteroid for at least one week prior to study registration
Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents; dexamethasone, or other corticosteroid medications, if used in the peri-operative period and/or during radiotherapy, must be tapered (no more than . mg/kg/day, max  mg/day dexamethasone) for at least one week before study registration; topical corticosteroids are acceptable
Medical need for the continuous administration of any drugs which affect CYPA though the use of low dose glucocorticoids (e.g. dexamethasone =<  mg daily or equivalent) for anorexia and /or nausea is permitted
Patients who are receiving high dose steroids (more than a dexamethasone-equivalent dose of  mg per day).
Dexamethasone at cumulative doses of greater than  mg or equivalent < weeks prior to study Day  is not allowed. Use of topical or inhaled steroids is acceptable
Patients with active autoimmune diseases or active immune suppressive therapy or inflammatory bowel disease; a low dose steroid daily administration (equivalent dexamethasone < mg/day) is acceptable
Systemic corticosteroid therapy is permitted provided dosing is no greater than  mg per day (dexamethasone or equivalent) on the day of vaccine administration.
Systemic corticosteroid therapy, >  mg of dexamethasone daily (or equivalent) at study enrollment
Concurrent Therapy \r\n* Patients who are receiving any other anticancer or investigational drug therapy\r\n* Patients requiring systemic treatment with either corticosteroids (greater than dexamethasone . mg/m^/day or the equivalent dose of other steroids) or other immunosuppressive medications within  days of study drug administration will be excluded; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the study
Stable topical steroid therapy with dexamethasone, clobetasol, or budesonide oral solutions ( min, four times a day) for seven days prior to study enrollment
Concurrent use of high dose steroids; chronic steroid use of <  mg dexamethasone or equivalent per day is permissible
A patient's daily total dose of dexamethasone must be =<  mg by day 
Patients receiving chronic, systemic treatment with corticosteroids (of more than  mg/day or equivalent of dexamethasone; doses of dexamethasone of up to  mg/day may be administered for less than  weeks) or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
Has not had prior systemic therapy for multiple myeloma. An emergency course of steroids (defined as no greater than  milligram [mg] of dexamethasone, or equivalent per day for a maximum of  days (that is, a total of  mg) is permitted. In addition, radiation therapy is permitted prior to study entry, during screening, and during Cycles - of study treatment as needed for lytic bone disease
Non-escalating corticosteroid dose (not exceeding more than  mg daily of dexamethasone oral) for >=  days
Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone  mg/day for  days) of corticosteroids before treatment
Patients needing more than  mg dexamethasone per day at the time of start of WBRT will not be eligible to participate in the study; however, patients will be allowed entry into the study if it is medically safe to reduce the daily dose of dexamethasone to  mg or less from the day of the start of WBRT; the dexamethasone dose for such patients may be increased beyond  mg per day during the course of treatment if medically necessary; this increased need for dose should be communicated to the studys principal investigator, Dr Mohindra at the University of Maryland
No more than  mg dexamethasone (or equivalent) per day
Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid (ie, less than or equal to the equivalent of dexamethasone  mg/day for  days; such a short course of steroid treatment must not have been given within  days of Cycle  Day ), for Cohort C, the induction and consolidation treatment along with the first Autologous stem cell transplantation (ASCT) are allowed)
Participants no longer need to be able to receive intravenous (IV) dexamethasone or an equivalent IV corticosteroid
Systemic corticosteroid therapy is permitted provided dosing is no greater than  mg per day (dexamethasone or equivalent) on the day of vaccine administration
Immunosuppressants: patients must be receiving a stable or decreasing dose of dexamethasone for at least  week prior to start of therapy AND dexamethasone dose must be =< . mg/kg/day AND =< a total daily dose of  mg/day
Stable dose of steroids for  days, no more than  mg dexamethasone (or equivalent) total per day
Requires treatment with high dose systemic corticosteroids defined as dexamethasone >  mg/day or bioequivalent for at least  consecutive days within  weeks of start of study drug
Patient requires more than  mg of dexamethasone daily or the equivalent
Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone  mg/day for  days) of corticosteroids before treatment
Corticosteroid therapies of >  mg/day prednisone, >  mg/day dexamethasone, >  mg/day hydrocortisone, or equivalent; oral, inhaled, or topical steroids are allowed during study as long as it does not exceed  mg/day hydrocortisone
Foreseeable condition which would preclude the reduction of steroids (dexamethasone) to a maximum of  mg BID within a week prior to apheresis -
Dexamethasone at cumulative doses greater than  mg or equivalent within  days prior to the first dose of study treatment is not allowed. Use of topical or inhaled steroids is acceptable.
Patients on total daily dose of dexamethasone greater than  mg/day
Patients taking greater than  mg daily of dexamethasone
Patients on greater than  mg per day of dexamethasone within the  weeks prior to admission for PVSRIPO infusion
Clinically stable and off or on low dose (no more than . mg/kg/day, maximum of  mg/day dexamethasone) corticosteroid for at least  week prior to study enrollment
Systemic corticosteroids (e.g. prednisone >= . mg/day or dexamethasone >=  mg/day) for the purpose of palliating tumor-related symptoms will not be allowed within  week of starting treatment on trial
High doses of systemic corticosteroids within  days prior to first dosing. High dose is considered as >  mg of dexamethasone a day (or equivalent) for >  consecutive days Exclusion Criteria (Part B):
Requirement of systemic corticosteroid therapy >  mg/day of dexamethasone or equivalent or requirement of increasing dose of systemic corticosteroids during the  days prior to the start of SL- treatment.
Contraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir) and proton-pump inhibitor (e.g. lansoprazole). Corticosteroid therapy in a dose equivalent to dexamethasone ? . mg/day or prednisone ?  mg/day. (Steroid use is allowed if necessary to treat spinal cord compression and/or hypocalcaemia.)
Patients must be on a steroid dose less than or equal to  mg of dexamethasone daily (or equivalent), and this dose must not have increased for at least  days prior to obtaining the enrollment.
Systemic corticosteroid therapy >  mg of dexamethasone daily (or equivalent) at study enrollment.
If a patient is on corticosteroids, he/she must be on a non-escalating corticosteroid dose (not exceeding more than  mg daily of dexamethasone oral) for >=  days
taking more than  mg of dexamethasone per day
Corticosteroid therapy at a dose equivalent to dexamethasone >  mg/day within  days prior to randomization
Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [i.e., less than or equal to the equivalent of dexamethasone  mg/day for  days; such a short course of steroid treatment must not have been given within  days of randomization]).
Systemic corticosteroid therapy >  mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.
For patients on oral corticosteroids, they must be stable clinically on corticosteroids or tapered off prior to starting the study drug; for patients taking dexamethasone, the dose should not exceed  mg QD (or  mg twice daily [BID]), if clinically stable, and the dose should not be escalated over entry dose level, if clinically possible; the patients dose of dexamethasone will be evaluated by the principal investigator (PI), the patients study physician, and/or the study pharmacist on a case by case basis for safety; all doses of oral corticosteroids will be reduced by %, unless oral corticosteroids are at physiologic dose (e.g. dexamethasone  mg, prednisone  mg, or cortisone  mg); it is recommended that oral corticosteroid doses be escalated back to full dose on day  ( days after aprepitant is discontinued)
Dexamethasone dose must be provided for treatment group assignment:\r\n* Group A: patients not on dexamethasone or on a dose =< . mg daily (or equivalent of an alternative corticosteroid)\r\n* Group B: patients who require dexamethasone >=  mg daily (or equivalent of an alternative corticosteroid)\r\n** Patients must have been on the group assignment dose of corticosteroids for at least  days prior to the dose of NT-I; corticosteroid dose changes prior to the start of treatment are allowed as long as they do not alter patients group assignment
Patient requires more than  mg of dexamethasone daily or the equivalent
More than  days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone  mg/day for  days]).
